Forte Biosciences, Inc.·Healthcare

Forte Biosciences has rebounded from near-liquidation, raising $150m this week and advancing FB102, its multi-indication anti-CD122 antibody, on multiple fronts. FB102 demonstrated statistically significant Phase 1b efficacy in Celiac disease, positioning FBRX as a potential frontrunner for first drug approval in this indication. Upcoming Phase 1b data in vitiligo and alopecia areata, both large and competitive markets, represent major catalysts for FBRX in 2024.

DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (Nasdaq: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced the pricing of a public offering of 5,709,936 shares of its common stock at a price to the public of $26.27 per share. In addition, Forte has granted the underwriters a 30-day option to purchase up to an additional 856,490 shares of its common stock at the public offering price, less the underwriting discounts and comm.

DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (Nasdaq: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced that it has commenced an underwritten public offering of shares of its common stock. In addition, Forte expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the number of shares of common stock. All of the shares of common stock are being offered by Forte. The proposed offering is su.

Forte Biosciences, Inc. (NASDAQ: FBRX - Get Free Report) was the target of some unusual options trading on Wednesday. Investors purchased 30,205 call options on the stock. This represents an increase of 1,663% compared to the typical daily volume of 1,713 call options. Forte Biosciences Stock Performance NASDAQ: FBRX opened at $24.86 on Thursday. The stock has

DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced its full year 2025 financial results and provided a business update. “The clinical development for FB102 continues to progress well with important readouts in 2026,” said Forte Biosciences CEO Paul Wagner, PhD. “The topline results from our phase 2 celiac disease study is expected in 2026. Based on.

DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on developing FB102, which is a proprietary anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune and autoimmune-related indications, today announced the issuance of equity inducement awards as required by the Nasdaq Stock Market Rules. In accordance with NASDAQ Listing Rule 5635(c)(4), the Compensation Committee of Forte's Boa.
Forte Biosciences, Inc. operates as a clinical-stage biopharmaceutical company in the United States. It is developing FB-102 program that addresses various autoimmune diseases, such as vitiligo and alopecia areata. The company is headquartered in Dallas, Texas.
Healthcare
Biotechnology
14
2017-04-13
3.20